ADA 25: Presenting Positive Data for 0602K Alone and in Combo w/Tirzepatide
9/17/2025
Cirius Therapeutics, Breakthrough T1D and UVA Health Collaborate on Phase 2 Study of MPC Inhibitor CIR-0602K in Type 1 Diabetes
6/20/2025
Cirius Announces Positive Data for MPC Inhibitor 0602K Alone and in Combination with Tirzepatide
6/4/2025
0602K + Tirzepatide Muscle Mass / Function and Adipose Transformation Data to be Presented at ADA Scientific Sessions
3/25/2025
Cirius to Present at Upcoming Healthcare Conferences
1/8/2025
Cirius to Present at WuXi Global Forum during J.P. Morgan Healthcare Week
6/5/2024
Late Breaking Poster Shows a Novel Oral Insulin Sensitizer Azemiglitazone (MSDC-0602K) Could Substantially Preserve Lean Muscle in Combination with Weight-Loss GLP1s